Harpoon Therapeutics Executives
Harpoon Therapeutics employs about 53 people. The company is managed by 12 executives with a total tenure of roughly 23 years, averaging almost 1.0 years of service per executive, having 4.42 employees per reported executive. Discussion of Harpoon Therapeutics' management performance can provide insight into the enterprise performance.
| Rachael Lester President Vice President of Corporate Development |
Harpoon |
Harpoon Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3566) % which means that it has lost $0.3566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8432) %, meaning that it created substantial loss on money invested by shareholders. Harpoon Therapeutics' management efficiency ratios could be used to measure how well Harpoon Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Harpoon Therapeutics Workforce Comparison
Harpoon Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,610. Harpoon Therapeutics holds roughly 53.0 in number of employees claiming about 3% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.82) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.73) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.73. Harpoon Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Harpoon Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Harpoon Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Harpoon Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jonathan Drachman over six months ago Acquisition by Jonathan Drachman of 415 shares of Harpoon Therapeutics subject to Rule 16b-3 | ||
Walker Luke Nathaniel over a year ago Acquisition by Walker Luke Nathaniel of 115000 shares of Harpoon Therapeutics subject to Rule 16b-3 | ||
Silvernail Lauren P over a year ago Acquisition by Silvernail Lauren P of 5000 shares of Harpoon Therapeutics subject to Rule 16b-3 | ||
Silvernail Lauren P over a year ago Acquisition by Silvernail Lauren P of 23000 shares of Harpoon Therapeutics subject to Rule 16b-3 | ||
Viney Joanne L over a year ago Acquisition by Viney Joanne L of 21028 shares of Harpoon Therapeutics subject to Rule 16b-3 |
Harpoon Therapeutics Notable Stakeholders
A Harpoon Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Harpoon Therapeutics often face trade-offs trying to please all of them. Harpoon Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Harpoon Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Julie MBA | CEO, President | Profile | |
| Rachael Lester | Vice President of Corporate Development | Profile | |
| Georgia Erbez | Consultant | Profile | |
| James JD | Chief Officer | Profile | |
| Luke MD | Chief Officer | Profile | |
| Wendy Chang | Chief Officer | Profile | |
| Michael Faerm | Interim Officer | Profile | |
| Chatan Charan | Technical Development | Profile | |
| Natalie MD | Consultant | Profile | |
| Holger Wesche | Chief Scientific Officer | Profile | |
| Banmeet Anand | Senior Medicine | Profile | |
| Haibo Wang | Senior Development | Profile |
Harpoon Therapeutics Workforce Analysis
Traditionally, organizations such as Harpoon Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Harpoon Therapeutics within its industry.Harpoon Therapeutics Manpower Efficiency
Return on Harpoon Therapeutics Manpower
| Revenue Per Employee | 704.5K | |
| Revenue Per Executive | 3.1M | |
| Net Loss Per Employee | 575.4K | |
| Net Loss Per Executive | 2.5M | |
| Working Capital Per Employee | 43.3K | |
| Working Capital Per Executive | 191.2K |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Harpoon Stock
If you are still planning to invest in Harpoon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Harpoon Therapeutics' history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |